We are live on ! Find out more
HQL

abrdn Life Sciences Investors

45 hedge funds and large institutions have $40.7M invested in abrdn Life Sciences Investors in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 16

6% more capital invested

Capital invested by funds: $38.3M → $40.7M (+$2.32M)

0.28% less ownership

Funds ownership: 11.52%11.24% (-0.28%)

10% less funds holding

Funds holding: 5045 (-5)

63% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 8

Holders
45
Holders Change
-5
Holders Change %
-10%
% of All Funds
1.2%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
20
Reduced
16
Closed
8
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
GAM
51
Gemmer Asset Management
California
+$19 +1 +6%

HQL Hedge Fund Activity: Q3 2016 in Review

45 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q3 2016, worth a combined $40.7M — up 6% from $38.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of HQL and 3 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 20 added.

The largest buyer was Citigroup, adding an estimated $769K. The largest seller was Advisors Asset Management, cutting an estimated $880K.

  • 45 institutional investors held abrdn Life Sciences Investors (HQL) as of Q3 2016, down from 50 in Q2 2016.
  • Funds reported $40.7M of abrdn Life Sciences Investors stock for Q3 2016, up 6% quarter-over-quarter.
  • 3 funds opened new abrdn Life Sciences Investors positions in Q3 2016 and 8 closed out, a net change of -5 holders.
  • The largest abrdn Life Sciences Investors buyer in Q3 2016 was Citigroup, an estimated $769K added.
  • The largest abrdn Life Sciences Investors seller in Q3 2016 was Advisors Asset Management, an estimated $880K sold.

Based on aggregated 13F filings for Q3 2016.